Functional heterogeneity among bone marrow-derived dendritic cells conditioned by Th1- and Th2-biasing cytokines for the generation of allogeneic cytotoxic T lymphocytes
Marimo Sato1,3,
Kenji Iwakabe1,
Akio Ohta1,2,
Masashi Sekimoto1,2,
Minoru Nakui1,
Toshiaki Koda2,
Shuichi Kimura3 and
Takashi Nishimura1,2
1 Section of Genetic Engineering, Research Center for Genetic Engineering and Cell Transplantation, Tokai University School of Medicine, Isehara 259-1193, Kanagawa, Japan
2 Section of Bacterial Infection, Institute of Immunological Science, Hokkaido University, Sapporo 060-0815, Hokkaido, Japan
3 Department of Practical Sciences, Showa Women's University, Setagaya 154-8533, Tokyo, Japan
Correspondence to:
T. Nishimura, Section of Bacterial Infection, Institute of Immunological Science, Hokkaido University, Sapporo 060-0815, Hokkaido, Japan
 |
Abstract
|
---|
Three distinct bone marrow (BM)-derived dendritic cells (BMDC) were expanded from BALB/c BM cells by culture with (i) granulocyte macrophage colony stimulating factor (GM-CSF) plus IL-3, (ii) GM-CSF, IL-3 plus Th1-biasing cytokines (IL-12 and IFN-
) or (iii) GM-CSF, IL-3 plus Th2-biasing cytokines (IL-4). All of these cells expressed the DC-specific marker CD11c, and were designated as BMDC0, BMDC1 and BMDC2 cells respectively. BMDC1 cells exhibited superior T cell-stimulating activity in allogeneic mixed lymphocyte culture (MLC), while BMDC2 showed inferior stimulating activity. Specifically, BMDC1, as compared with BMDC2, induced a higher frequency of IFN-
-producing CD8+ T cells in MLC. Moreover, BMDC1, but not BMDC2, were strong inducers of H-2d-specific cytotoxic T lymphocytes (CTL) in MLC. BMDC0 always showed intermediate stimulatory activity; however, when BMDC0 were cultured with IFN-
, they differentiated into BMDC1-like stimulator cells concomitant with the up-regulation of both MHC antigens and co-stimulatory molecules. In contrast, BMDC2 were refractory to differentiation into superior stimulator cells by treatment with IFN-
, although this treatment enhanced MHC expression. These findings indicate that Th1- and Th2-biasing cytokines, in addition to their effect on Th cell differentiation, may play a critical role in the functional skewing of DC. These findings have important implications for the development of DC-based immunotherapies.
Keywords: cytokine, cytotoxic T lymphocyte, dendritic cells, immunotherapy, Th1/Th2 balance
 |
Introduction
|
---|
Antigen-presenting cells (APC) play a central role in the triggering of both innate and acquired immunity (1). Among APC, dendritic cells (DC) are the most capable inducers of primary and secondary immune responses (2,3). DC take up foreign antigens through pattern recognition receptors, combine peptide fragments of these antigens with MHC class I and class II molecules, and stimulate naive CD8+ T and CD4+ cells (4,5). In addition, DC can communicate with T cells directly through cell adhesion molecules or indirectly via cytokines such as IL-12, IL-18 and IL-10 (69). These interactions influence the differentiation of naive CD4+ T cells into Th1 or Th2 cells that mediate cellular and humoral immunity respectively (1012).
Recent work has demonstrated functional heterogeneity among DC subsets. In the mouse system, CD11c+CD8
+ lymphoid DC produce high levels of IL-12 (13). Moreover, CD8
+ DC were demonstrated to produce IFN-
in response to IL-12 (14). Thus, lymphoid DC subsets, which are termed DC1, appear to be involved in the activation of Th1 immunity. In contrast, CD11c+CD8
CD11b+ myeloid DC, termed DC2, produce low levels of IL-12 compared with DC1 and play a critical role in the development of Th2 immunity (13). Since an imbalance of Th1/Th2 immunity causes the onset of various immune diseases (15,16), it is of great importance to investigate how the functional maturation of DC is regulated.
In a previous report (17), we proposed that three distinct CD11c+ DC subsets, which were expanded from bone marrow (BM) cells under neutral conditions [granulocyte macrophage colony stimulating factor (GM-CSF) plus IL-3], Th1-biasing conditions (GM-CSF, IL-3, IL-12 plus IFN-
) or Th2-biasing conditions (GM-CSF, IL-3 plus IL-4) exhibited functional differences in the development of Th1 or Th2 cells from naive Th cells isolated from TCR transgenic mice. In the present paper, we designated these DC subsets as BMDC0, BMDC1 or BMDC2 and investigated their role on the generation of allogeneic cytotoxic T lymphocytes (CTL) in mixed lymphocyte culture (MLC). Among three BMDC subsets, CD11c+CD11b+ BMDC1 cells expanded under Th1-biasing conditions expressed the highest levels of MHC class I, MHC class II and co-stimulatory molecules such as B7-1 and CD40, and exhibited the most potent stimulatory activity for the generation of IFN-
-producing CD8+ CTL. In contrast, BMDC2 induced under Th2-biasing conditions poorly supported the induction of alloreactive CTL. These data further indicated that Th1- or Th2-biasing cytokines produced during the early immune events may drive the functional maturation of DC and subsequently regulate Th1-dominant cellular immunity or Th2- dominant humoral immunity.
 |
Methods
|
---|
Animals
Female BALB/c and C57BL/6 mice were obtained from Charles River Japan (Yokohama, Japan) and used at 56 weeks of age.
Induction of DC from BM cells
BM cells obtained from BALB/c mouse femora were cultured under three distinct culture conditions in 12-well plates (Costar, New York City) for 4 days. DC0 were induced by culture of BM cells (5x106 cells/well) in the presence of GM-CSF (20 ng/ml) and IL-3 (20 ng/ml). DC1 were induced by culture of BM cells in the presence of IFN-
(20 ng/ml) and IL-12 (20 U/ml) in addition to GM-CSF plus IL-3. DC2 were induced by culture of BM cells in the presence of IL-4 (20 ng/ml) in addition to GM-CSF plus IL-3. At 23 days after the initiation of culture, non-adherent lymphoid cells contaminating in the BM cells were removed from the culture and replaced with fresh medium containing cytokine cocktails. DC cells harvested from 4 day culture of BM cells were used as BMDC subsets. Recombinant IL-12 was kindly donated by Genetics Institute (Cambridge, MA). IL-3, IL-4 and IFN-
were purchased from PharMingen (San Diego, CA) and recombinant GM-CSF was purchased from PeproTech EC (London, UK). To examine the conversion of BMDC0 or BMDC2 cells into BMDC1-like stimulator cells, BMDC0 or BMDC2 cells were cultured under neutral conditions (for BMDC0) or Th2-biasing conditions (for BMDC2) for 4 days, then the cells harvested from each culture were pretreated with IFN-
for 2 days and used in MLC.
Generation of CTL in mixed lymphocyte culture (MLC)
C57BL/6 mouse spleen cells (5x106 cells) were co-cultured with either BMDC0, BMDC1 or BMDC2 (2x105 cells), which were inactivated by pretreatment with mitomycin C (60 µg/ml; Kyowa Hakko Kogyo, Tokyo, Japan). Cells were co-cultured for 4 days in round-bottomed 5-ml tube (Falcon; Becton Dickinson, San Jose, CA). After culture, cells were harvested and used for phenotypic analysis, intracellular cytokine expression and cytotoxicity.
Flow cytometry
The phenotypic characterization of DC and CTL was carried out using FACSCalibur (Becton Dickinson) and CellQuest software. The mAb used in our experiments [phycoerythrin (PE)-conjugated anti-CD11c mAb, FITC-conjugated anti-CD11b mAb, FITC-conjugated anti-H-2Kd mAb, FITC-conjugated anti-I-Ad mAb, FITC-conjugated anti-CD1d, FITC-conjugated anti-CD40 mAb, FITC-conjugated anti-CD80 mAb and FITC-conjugated anti-CD11a mAb] were purchased from PharMingen. Detailed procedures for staining and sorting were described previously (18). Fluorescence data were collected with logarithmic amplification. For each sample, data from 10,000 volume-gated viable cells were collected. In some experiments, CD8+ T cells isolated from MLC by sorting with FACS vantage (Becton Dickinson) were used for cytotoxicity assay.
Intracellular cytokine expression
For the detection of cytoplasmic cytokine expression, cells stimulated with immobilized anti-CD3 mAb for 6 h in the presence of Brefeldin A were first stained with PerCP-conjugated anti-CD8 mAb, fixed with 4% paraformaldehyde, treated with permeabilizing solution (50 mM NaCl, 5 mM EDTA, 0.02% NaN3 and 0.5% Triton X-100, pH 7.5), and then the fixed cells were stained with PE-conjugated anti-IL-4 mAb and FITC-conjugated anti-IFN-
mAb for 45 min on ice. The percentage of cells expressing cytoplasmic IL-4 or IFN-
was determined by flow cytometry (FACSCalibur) (19). PerCP-conjugated anti-CD8 mAb, PE-conjugated anti-IL-4 mAb and FITC-conjugated anti-IFN-
mAb were purchased from PharMingen.
Cytotoxicity assay
The cytotoxicity mediated by CTL generated in MLC was measured by 4 h 51Cr-release assay as described previously (20). H-2d-specific cytotoxicity was determined using BALB/c-derived P815 mastocytoma cells (H-2d) as target cells. As control, C57BL/6-derived MBL-2 T lymphoma cells (H-2b) were used. The percent cytotoxicity was calculated as described previously (20).
 |
Results
|
---|
Expansion of three distinct DC subsets from BM cells by culture with different cytokine cocktails
BALB/c BM cells were cultured under three different conditions for 4 days as follows: (i) in the presence of GM-CSF plus IL-3 (neutral conditions), (ii) in the presence of IL-12 and IFN-
in addition to GM-CSF plus IL-3 (Th1-biasing conditions), and (iii) in the presence of IL-4 in addition to GM-CSF plus IL-3 (Th2-biasing conditions). We designated these BM-derived DC subsets induced by either neutral, Th1- or Th2-biasing cytokines as BMDC0, BMDC1 and BMDC2 respectively. As shown in Fig. 1
, all BMDC subsets expressed the CD11c antigen, a marker for DC, at the same levels. However, the expression profile of functional cell-surface molecules among the three BMDC subsets is very different. As illustrated in Fig. 1
, BMDC1 expressed the highest levels of MHC class I, MHC class II, CD1d, CD40, B7-1 and LFA-1, compared with BMDC0 and BMDC2. BMDC1 also expressed higher levels of the CD11b marker than BMDC0 and BMDC2. However, only a small percentage (11%) of BMDC1 dully expressed F4/80 macrophage marker as well as BMDC0 (6.9%) and BMDC2 (7.1%) (data not shown). Moreover, it was demonstrated that all BMDC subsets expressed high levels of Thy-1 but not CD8 antigens (data not shown). Therefore, BMDC1 appeared to belong to myeloid DC subset but not lymphoid DC subsets. BMDC1 also showed unique morphological characteristics, including a small size, a star-like shape and sharp dendrites (Fig. 2
). BMDC2 were the largest cells and had long dendrites. BMDC0 had an intermediate size between BMDC1 and BMDC2.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 1. Phenotypic characterization of functional cell surface molecules on BMDC subsets. BMDC0, BMDC1 or BMDC2 cells were induced as described in Methods and their phenotypic characteristics were determined by FACSCalibur 4 days after the initiation of culture. DC were stained with PE-labeled anti-CD11c mAb (A) combined with FITC-labeled anti-CD11b mAb (B), FITC-labeled anti-H-2d mAb (C), FITC-labeled anti-I-Ad mAb (D), FITC-labeled anti-CD1d mAb (E), FITC-labeled anti-CD40 mAb (F), FITC-labeled anti-CD80 mAb (G) and FITC-labeled anti-LFA-1 mAb (H). The expression of functional molecules (BH) on gated CD11c+ DC cells was determined by FACSCalibur. The fine solid, bold and dotted lines reveal the staining pattern of BMDC0, BMDC1 and BMDC2 cells respectively. The bars represent the negative area defined by unstained control DC cells.
|
|
Functional differences among BMDC0, BMDC1 and BMDC2 subsets for the generation of CTL in allogeneic MLC
To demonstrate functional differences among BMDC0, BMDC1 and BMDC2, we compared their stimulating effect on the generation of CTL in allogeneic MLC. MLC was carried out by co-culturing C57BL/6 mouse spleen cells (5x106 cells) with 2x105 mitomycin C-treated BALB/c-derived BMDC0, BMDC1 or BMDC2 for 4 days. Consistent with our observation that BMDC1 expressed high levels of MHC and co-stimulatory molecules, critically important for the stimulation of allogeneic T cells, the most potent cell proliferation was induced by stimulation with BMDC1 (data not shown). Cells from MLC stimulated with BMDC1 contained a higher percentage of CD8+ T cells (23.4%) compared with MLC stimulated with BMDC0 (13.7%) or BMDC2 (11.1%) (Fig. 3A
). These data strongly suggested that BMDC1 are the most efficient stimulator cells for inducing expansion of allogeneic CD8+ T cells. The potent stimulatory effect of BMDC1 on the generation of functional CD8+ T cells was also demonstrated by investigating intracellular cytokine expression in CD8+ T cells. The highest percentage (31.6%) of IFN-
-producing CD8+ T (TC1) cells was induced in MLC using BMDC1 stimulator cells (Fig. 3B
). In sharp contrast, BMDC2 were poor stimulators for the induction of TC1 cells (10.8%). BMDC0 cells always revealed a intermediate stimulatory activity for the induction of TC1 cells (16.8%). Consistent with the efficient function of BMDC1 for the induction of IFN-
-producing TC1 cells, BMDC1 were also the most effective in stimulating the generation of allogeneic CTL in MLC (Fig. 4
). MLC stimulated with BMDC1 stimulator cells showed the highest cytotoxicity against H-2d-positive P815 mastocytoma cells (Fig. 4A
), but not against H-2b-positive MBL-2 T lymphoma cells (Fig. 4B
). Intermediate levels of CTL activity were induced by stimulation with BMDC0, whereas negligible cytotoxicity was induced by stimulation with BMDC2 (Fig. 4A
). To exclude the possibility that the contaminated CD11c BM cells might show potent stimulatory activity on CTL generation, we also examined the different stimulatory activity between BMDC subsets using FACS-sorted CD11c+ BMDC1 and BMDC2. As shown in Fig. 5
(A), CD11c+ BMDC1 also showed stronger stimulatory activity for the generation of IFN-
-producing CTL compared with CD11c+ BMDC2 subsets. Therefore, the functional heterogeneity among BMDC subsets for CTL induction was not derived from contaminated CD11c BM cells. As shown in Fig. 5
(B), CD8+ CTL were responsible for the cytotoxicity induced in MLC by stimulation with BMDC1. From these results, we concluded that BMDC1 cells expanded from BM cells by culture under Th1-biasing conditions are the most potent stimulator cells for the generation of IFN-
-producing CD8+ CTL.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 4. Functional differences among BMDC0, BMDC1 and BMDC2 subsets for the generation of allogeneic CTL in MLC. C57BL/6 mouse spleen cells (H-2b) were stimulated with either none, BMDC0, BMDC1 or BMDC2 derived from BALB/c BM (H-2d) in MLC for 4 days. Cells were harvested from the MLC and examined for their cytotoxicity against P815 (H-2d) (A) or MBL-2 (H-2b) (B) cells in a 4 h 51Cr-release assay. The bars represent mean ± SE of triplicate samples.
|
|
BMDC0, but not BMDC2, can be converted into BMDC1-like stimulator cells by treatment with IFN-
We next examined whether it was possible to convert BMDC0 and BMDC2 into BMDC1-like stimulator cells by treatment with IFN-
before MLC. BM cells were cultured under neutral conditions (for BMDC0) or Th2-biasing conditions (for BMDC2) for 4 days, then the cells were harvested from each culture and treated with IFN-
for 2 days before use in MLC. As shown in Fig. 6
, treatment with IFN-
greatly enhanced expression of MHC class I and class II molecules on both BMDC0 and BMDC2, reaching levels as high as those of BMDC1. Interestingly, expression of co-stimulatory molecules such as CD40 and B7-1 was also enhanced by treatment of BMDC0 with IFN-
, while no significant up-regulation of these molecules was observed when BMDC2 cells were treated with IFN-
. Such conversion of BMDC0 into BMDC1-like cells was also induced with lipolysaccharide stimulation, but not by culture with IL-12 or IL-4 (data not shown). Moreover, removal of IFN-
from BMDC1 for 2 days caused a marked reduction of MHC molecules and co-stimulatory molecules (data not shown). Therefore, IFN-
appeared to be the critical factor for the development of BMDC1-like APC.
Consistent with our finding (Fig. 6
) that IFN-
-treatment increased expression of MHC and co-stimulatory molecules on BMDC0, but not BMDC2, IFN-
-treated BMDC0, but not BMDC2, were efficient stimulators in allogeneic MLC (Figs 7 and 8
). Analysis of intracellular cytokine expression (Fig. 7
) further demonstrated that the stimulatory activity of BMDC0 for the induction of IFN-
-producing CD8+ T (TC1) cells was markedly enhanced by treatment of BMDC0 with IFN-
for 2 days (Fig. 7A and C
). In sharp contrast, no significant increase in the generation of TC1 was observed when BMDC2 were treated with IFN-
(Fig. 7B and D
). The inability of BMDC2 cells to differentiate into BMDC1-like stimulator cells was further confirmed by demonstrating that both untreated and IFN-
-treated BMDC2 were poor stimulators for the generation of allogeneic CTL in MLC (Fig. 8
). In sharp contrast, BMDC0 treated with IFN-
were very potent stimulators for the generation of CTL in MLC, as was the case for BMDC1. The importance of IFN-
for these effects was underscored by demonstrating that the potent stimulatory activity of BMDC1 was greatly decreased by depleting IFN-
from the culture for 2 days (data not shown).
 |
Discussion
|
---|
The body is protected from pathogenic antigens by two distinct immune systems, innate immunity and acquired immunity (1,2,20,21). Recent work has suggested that professional APC such as DC and macrophages play a critical role in bridging both immune systems through direct cellcell contact or the production of cytokines (69). For example, NKT cells, one of the major effector cell populations in innate immunity, can be activated by DC through CD1d-restricted presentation of glycolipid antigens together with adhesion molecule-mediated cellcell interactions and cytokines (8,22). Moreover, DC exhibit potent antigen-processing activity and can present MHC class II-bound antigenic peptides to mainstream CD4+ Th cells (6,23). When DC interact with NKT or Th cells, DC are conditioned by endogenously produced cytokines such as IL-12, IL-18, IFN-
, IL-2, IL-10 and IL-4, and these conditioned DC can then activate CD8+ T cells to differentiate into functionally maturate CTL that produce IFN-
(6,7,24). Thus, DC play a pivotal role in the initiation and progression of immune responses.
It has recently been suggested that functional heterogeneity may exist among DC subsets (13,14,17,25). CD11c+CD8
+ lymphoid DC were proposed to be key APC for the development of Th1 immunity (13,14). In contrast, CD11c+CD11b+CD8
myeloid DC play a critical role in the development of Th2 immunity (13). However, different results were obtained in analyzing the functions of mouse and human DC subsets (26); it is therefore likely that other DC subsets with different functions may exist. It is now recognized that the Th1/Th2 balance is important for immunoregulation and that its imbalance causes various immune diseases (11,12,15,16). It is therefore critically important to investigate factors that influence the functional maturation of DC and, in turn, affect the differentiation of naive CD4+ T cells into Th1 or Th2 cells.
When we initiated the present experiments, our working hypothesis was as follows. Since the polarization of immune responses into Th1- or Th2-dominant immunity is determined at the local site where antigen-processed DC interact with naive Th, we speculated that: (i) Th-derived cytokines and cytokines produced by innate immune cells may affect the differentiation of functionally distinct DC, and (ii) that DC-derived cytokines may, in part, determine Th1 and Th2 differentiation (3,20). In keeping with our hypothesis, we previously demonstrated that DC differentiated from BM cells in the presence of Th1-inducing cytokines such as IL-12 and IFN-
facilitate the differentiation of Th1 cells from naive Th cells, while DC induced in the presence of Th2-inducing cytokine IL-4 accelerate the differentiation of Th2 cells (17). In the present paper, we further demonstrated that Th1- and Th2-biasing cytokines may be important for the functional skewing of BM-derived DC subsets with functional heterogeneity for the generation of allogeneic CTL in MLC.
As shown in Figs 3 and 4
, BMDC1 expanded from BM cells using Th1-biasing cytokines exhibited the most potent stimulator activity for the induction of IFN-
-producing CD8+ T cells (TC1) and antigen-specific CTL in allogeneic MLC. The higher stimulating activity of BMDC1 compared with BMDC0 or BMDC2 appeared to be related to their increased expression levels of MHC class I, MHC class II and co-stimulatory molecules such as CD40, B7-1 and LFA-1 (Fig. 1
). In allogeneic MLC, it has been demonstrated that MHC class I is critically important for the generation of allogeneic CD8+ CTL (27,28). Consistent with this finding, BMDC0 expressing low levels of MHC class I were poor stimulators in MLC (Figs 3 and 4
). However, when BMDC0 were treated with IFN-
, they converted into BMDC1-like stimulator cells, concomitant with enhanced expression of both MHC and co-stimulatory molecules (Figs 68

). Although IL-4 has been reported to stimulate macrophage expression of MHC class II (29), BMDC0 cultured with IL-4 in the presence of GM-CSF plus IL-3 did not convert into BMDC1-like APC (data not shown). Therefore, the differentiation of BMDC1 cells from BM cells appeared to be accelerated by IFN-
but not by IL-4. However, the fact that lipopolysaccharide also allowed the conversion of BMDC0 into BMDC1-like APC (data not shown) suggested that another factor indifferent to Th1 and Th2 cytokines might be involved in BMDC1 differentiation from BMDC0. In contrast to BMDC0, BMDC2 could not be differentiated into BMDC1-like stimulator cells by treatment with IFN-
, even though this treatment strongly enhanced MHC surface expression (Fig. 6
). Different characteristics of IFN-
-treated BMDC0 and BMDC2 include the expression pattern of co-stimulatory molecules such as CD40, B7-1 and LFA-1, which play an important role in CTL generation (3032). Indeed, we have evidence that LFA-1/ICAM-1 interaction between T cells and DC is critical for CTL generation (data not shown), consistent with previous reports (32). Therefore, the high levels of co-stimulatory molecules, in addition to MHC class I, appeared to be required for CTL generation in MLC. Moreover, we previously found that IL-12-producing ability differs significantly among the three BMDC subsets (17). Specifically, BMDC0 and BMDC1 produced high levels of IL-12, while BMDC2 produced very low levels of IL-12. This is an important difference, because IL-12 acts as a key cytokine for the development of Th1 and CTL through the induction of IFN-
(20). Here, we again confirmed that both untreated and IFN-
-treated BMDC2 produce very low levels of IL-12, while both BMDC0 and BMDC1 can produce significant levels of IL-12 irrespective of IFN-
treatment (data not shown). Therefore, MHC and co-stimulatory molecule expression and the ability to produce IL-12 appeared to be critically important factors for the induction of Th1- and Tc1-dominant cellular immunity by BMDC subsets.
Consistent with our previous result (17), BMDC1 cells also facilitated the generation of IFN-
-producing Th cells compared with BMDC2 (data not shown). However, we could not demonstrate that BMDC2 stimulated the generation of IL-4-producing Th2 or Tc2 during MLC. This might be because of the difficulty of the induction of IL-4-producing Th2 or Tc2 cells from bulk wild-type mouse spleen T cells in MLC. In allogeneic MLC with spleen cells and BMDC1, MHC class I-reactive CD8+ T cells appeared to be major responder cells rather than CD4+ Th cells and conditioned BMDC1 cells could bypass the function of Th cells in the generation of CTL. Indeed, we have already demonstrated that Th1-cytokine conditioned BMDC1 allowed the differentiation of CTL from purified CD8+ T cells in the absence of CD4+ T cells (data not shown). Therefore, Th1 cytokine-conditioned BMDC1 will become good tool for immunotherapy.
Recently, DC-based immunotherapy has been applied to malignant and infectious diseases (33,34). In most protocols for immunotherapy, DC expanded with GM-CSF plus IL-4 have been used (3537). However, our previous (17) and present results strongly suggest that myeloid-type DC expanded in the presence of Th2-biasing cytokine IL-4 may not be optimal for application to DC-based immunotherapy. Although we demonstrate that BMDC1 and IFN-
-treated BMDC0 are potent stimulators for the development of allogeneic CTL or peptide-specific Th1 cells, it will be necessary to investigate whether these BMDC subsets can process intact protein antigens and support the generation of Th1 and CTL specific to the digested antigenic peptide. Recent studies in mice suggested that lymphoid DC play a critical role in the induction of Th1-dominant immunity, while myeloid DC are important for the induction of Th2-dominant immunity (13). However, we demonstrated that CD11c+CD11b+CD8
myeloid BMDC1 support the development of Th1- and Tc1-dominant cellular immunity. Further studies will be required to select the most suitable DC subsets for DC-based immunotherapy.
 |
Acknowledgments
|
---|
We would like to thank Dr Luc Van Kaer (Howard Hughes Medical Institute, Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN) for reviewing this manuscript. We also thank Dr S. H. Herrmann and Dr M. Kobayashi (Genetics Institute, Cambridge, MA) for their kind gift of IL-12.
 |
Abbreviations
|
---|
APC antigen-presenting cell |
BM bone marrow |
BMDC bone marrow-derived dendritic cells |
CTL cytotoxic T lymphocyte |
DC dendritic cells |
GM-CSF granulocyte macrophage colony stimulating factor |
MLC mixed lymphocyte culture |
 |
Notes
|
---|
Transmitting editor: K. Sugamura
Received 13 October 1999,
accepted 19 November 1999.
 |
References
|
---|
-
Banchereau, J. and Steinman, R. M. 1998. Dendritic cells and the control of immunity. Nature 392:245.[ISI][Medline]
-
Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271.[ISI][Medline]
-
Palucka, K. and Banchereau, J. 1999. Dendritic cells: a link between innate and adaptive immunity. J. Clin. Immunol. 19:12.[ISI][Medline]
-
Watts, C. 1997. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. 15:821.[ISI][Medline]
-
Pierre, P., Turley, S. J., Gatti, E., Hull, M., Meltzer, J., Mirza, A., Inaba, K., Steinman, R. M. and Mellman, I. 1997. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388:787.[ISI][Medline]
-
Ridge, J. P., Rosa, F. D. and Matzinger, P. 1998. A conditioned dendritic cell can be temporal bridge between a CD4+ T-helper and T-killer cell. Nature 393:474.[ISI][Medline]
-
Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. and Melief, C. J. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40CD40L interactions. Nature 393:480.[ISI][Medline]
-
Kitamura, H., Iwakabe, K., Yahata, T., Nishimura, S., Ohta, A., Ohmi, Y., Sato, M., Takeda, K., Okumura, K., Van Kaer, L., Kawano, T., Taniguchi, M. and Nishimura, T. 1999. The natural killer T (NKT) cell ligand
-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189:1121.[Abstract/Free Full Text]
-
Stoll, S., Jonuleit, H., Schmitt, E., Muller, G., Yamaguchi, H., Kurimoto, M., Knop, J. and Enk, A. H. 1998. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur. J. Immunol. 28:3231.[ISI][Medline]
-
Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A. and Alber, G. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity. TT help via APC activation. J. Exp. Med. 184:747.[Abstract]
-
Mosmann, T. R. and Sad, S. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17:138.[ISI][Medline]
-
O'Garra, A. 1998. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8:275.[ISI][Medline]
-
Maldonado-Lopez, R. M., Smedt, T. D., Michel, P., Godfroid, J., Pajak, B., Heirman, C., Thielemans, K., Leo, O., Urbain, J. and Moser, M. 1999. CD8
+ and CD8
subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med. 189:587.[Abstract/Free Full Text]
-
Ohteki, T., Suzue, K., Maki, C., Ito, M., Nakamura, M. and Koyasu, S. 1999. Interleukin 12-dependent interferon
production by CD8
+ lymphoid dendritic cells. J. Exp. Med. 189:1981.[Abstract/Free Full Text]
-
Liblau, R. S., Singer, S. M. and McDevitt, H. O. 1995. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 16:34.[ISI][Medline]
-
Nishimura, T. and Ohta, A. 1999. A critical role for antigen-specific Th1 cells in acute liver injury in mice. J. Immunol. 162:6503.[Abstract/Free Full Text]
-
Sato, M., Iwakabe, K., Kimura, S. and Nishimura, T. 1999. Functional skewing of bone marrow dendritic cells by Th1- or Th2-inducing cytokines. Immunol. Lett. 67:63.[ISI][Medline]
-
Nishimura, T., Takeuchi, Y., Ichikawa, Y., Gao, X., Akatsuka, A., Tamaoki, N., Yagita, H., Okumura, K. and Habu, S. 1990. Thymic stromal cell clone with nursing activity supports the growth and differentiation of murine CD4+8+ thymocytes in vitro. J. Immunol. 145:4012.[Abstract/Free Full Text]
-
Matsuyama, T., Urano, K., Ohkido, M., Ozawa, H., Ohta, A., Kaneko, S., Yahata, T. and Nishimura, T. 1999. The quantitative and qualitative defect of CD4+CD45RO+ memory-type T cells are involved in the abnormality of Th1 immunity in atopic dermatitis patients. Clin. Exp. Allergy 29:687.[ISI][Medline]
-
Nishimura, T., Brakoff, S. J. and Herrmann, S. H. 1989. Inhibition of lymphokine-activated killer cell-mediated cytotoxicity by phorbol ester. J. Immunol. 142:2155.[Abstract/Free Full Text]
-
Fearon, D. T. and Locksley, R. M. 1996. The instructive role of innate immunity in the acquired immune response. Science 2272:50.
-
Kawano., T, Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., Koseki, H. and Taniguchi, M. 1997. CD1d-restricted and TCR-mediated activation of V
14 NKT cells by glycosylceramides. Science 278:529.
-
Stumbles. P. A., Thomas, J. A., Pimm, C. L., Lee, P. T., Venaille, T. J., Proksch, S. and Holt, 1 P. G. 998. Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity. J. Exp. Med. 188:2019.
-
Burdin, N., Brossay, L. and Kronenberg, M. 1999. Immunization with
-galactosylceramide polarizes CD1-reactive NKT cells towards Th2 cytokine synthesis. Eur. J. Immunol. 29:2014.[ISI][Medline]
-
Ria, F., Penna, G. and Adorini, L. 1998. Th1 cells induce and Th2 inhibit antigen-dependent IL-12 secretion by dendritic cells. Eur. J. Immunol. 28:2003.[ISI][Medline]
-
Rissoan, M. C., Soumelis, V., Kadowaki, N., Grouard, G., Briere, F., de Waal Malefyt, R. and Liu, Y. J. 1999. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283:1183.[Abstract/Free Full Text]
-
Connolly, J. M., Potter, T. A., Wormstall, E. M. and Hansen, T. H. 1988, The Lyt-2 molecules recognizes residues in the class I
3 domain in allogenic cytotoxic T cell responses. J. Exp. Med. 168:325.[Abstract]
-
Chouaib, S., Bensussan, A., Termijtelen, A. M., Andreeff, M., Marchiol-Fournigault, C., Fradelizi, D. and Dupont, B. 1988. Allogeneic T cell activation triggering by MHC class I antigens. J. Immunol. 141:423.[Abstract/Free Full Text]
-
Doyle, A. G., Herbein, G., Montaner, L. J., Minty, A. J., Caput, D., Ferrara, P. and Gordon, S. 1994. Interleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-
. Eur. J. Immunol. 24:1441.[ISI][Medline]
-
Bennett, S. R., Carbone, F. R., Karamails, F., Flavell, R. A., Miller, J. F. and Heath, W. R. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478.[ISI][Medline]
-
Harding, F. A. and Allison, J. P. 1993. CD28B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177:1791.[Abstract]
-
Inaba, K. and Steinman, R. M. 1987, Monoclonal antibodies to LFA-1 and to CD4 inhibit the mixed leukocyte reaction after the antigen-dependent clustering of dendritic cells and T lymphocytes. J. Exp. Med. 165:1403.[Abstract]
-
Gilboa, E., Nair, S. K. and Lyerly, H. K. 1998. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. 46:82.[ISI][Medline]
-
Girolomoni, G. and Ricciardi-Castagonoli, P. 1997. Dendritic cells hold promise for immunotherapy. Immunol. Today 18:102.[ISI][Medline]
-
Okada, H., Tahara, H., Shurin, M. R., Attanucci, J., Giezeman-Smits, K. M., Fellows, W. K., Lotze, M. T., Chambers, W. H. and Bozik, M. E. 1998. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int. J. Cancer 78:196.[ISI][Medline]
-
Tuting, T., Wilson, C. C., Martin, D. M., Kasamon, Y. L., Rowles, J., Ma, D. I., Slingluff C. L., Jr, Wagner, S. N., van der Bruggen, P., Baar, J., Lotze, M. T. and Storkus, W. J. 1998. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-
. J. Immunol. 1260:1139.
-
Bourguin, I., Moser, M., Buzoni-Gatel, D., Tielemans, F., Bout, D., Urbain, J. and Leo, O, 1998. Murine dendritic cells pulsed in vitro with Toxoplasma gondi antigens induce protective immunity in vivo. Infect. Immun. 66:4867.[Abstract/Free Full Text]